GlassScriptPhysician profile
John David Sprandio
NPI 1487819769
$10,366.81
in general payments reported to CMS, 2019-2025
67 companies · $2,542 in 2025
The $2,542 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,353 · 2020: $714 · 2021: $451 · 2022: $962 · 2023: $2,034 · 2024: $2,311 · 2025: $2,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,699 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,698.62 |
| Education | $188.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $900.78 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $871.75 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Shield Therapeutics INC | $688.65 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $642.95 | 2019-2025 | Imfinzi, Calquence, Tagrisso |
| Abbvie INC. | $433.55 | 2019-2025 | Venclexta |
| Merck Sharp & Dohme LLC | $421.50 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $396.57 | 2019-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $390.11 | 2019-2025 | |
| Daiichi Sankyo INC. | $356.23 | 2021-2025 | Enhertu, Datroway |
| Genzyme Corporation | $320.79 | 2020-2025 | |
| Janssen Biotech, INC. | $280.30 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Pharmacyclics LLC, An Abbvie Company | $250.36 | 2019-2023 | Imbruvica |
| Genentech USA, INC. | $225.15 | 2019-2025 | Venclexta, Tecentriq |
| Eisai INC. | $222.74 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $222.42 | 2019-2025 | Libtayo |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $222.26 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Blueprint Medicines Corporation | $217.50 | 2020-2024 | Ayvakit |
| Glaxosmithkline, LLC. | $212.70 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Amgen INC. | $193.19 | 2019-2023 | Xgeva, Nplate, Vectibix |
| Servier Pharmaceuticals LLC | $184.23 | 2021-2024 | |
| Seagen INC. | $175.78 | 2019-2023 | Padcev |
| Array Biopharma INC | $164.11 | 2022-2025 | Braftovi, Mektovi, Paxlovid |
| Astellas Pharma US INC | $155.03 | 2022-2025 | Vyloy, Padcev, Xospata |
| Emd Serono, INC. | $149.82 | 2023-2024 | Bavencio |
| Mirati Therapeutics, INC. | $146.90 | 2023-2024 | Krazati |
| Gilead Sciences, INC. | $129.57 | 2021-2025 | Trodelvy |
| Puma Biotechnology, INC. | $116.62 | 2019-2025 | |
| Genmab U.S., INC. | $116.40 | 2022-2025 | Tivdak |
| Jazz Pharmaceuticals INC. | $105.33 | 2019-2021 | |
| Incyte Corporation | $90.21 | 2019-2024 | Monjuvi, Pemazyre |
| Sobi, INC | $86.63 | 2023-2025 | |
| Exelixis INC. | $81.91 | 2019-2023 | Cabometyx |
| Pharmaessentia USA Corporation | $71.75 | 2023-2024 | Besremi |
| Kite Pharma, INC. | $71.11 | 2020-2024 | Yescarta |
| Caris Mpi, INC. | $70.77 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $69.10 | 2019-2025 | Orserdu |
| Morphosys, US INC. | $63.09 | 2023 | Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $61.67 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $55.73 | 2022 | |
| Alexion Pharmaceuticals, INC. | $55.09 | 2024-2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $49.33 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $43.01 | 2022 | |
| Tersera Therapeutics LLC | $42.79 | 2022-2025 | Zoladex |
| G1 Therapeutics, INC. | $38.08 | 2022 | |
| Adc Therapeutics America, INC. | $35.67 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $34.00 | 2023-2024 | Orgovyx |
| Spectrum Pharmaceuticals INC. | $33.97 | 2023-2025 | Rolvedon |
| Tesaro, INC. | $30.96 | 2019 | |
| Dendreon Pharmaceuticals LLC | $30.71 | 2020 | |
| Beone Medicines USA, INC. | $30.28 | 2025 | Tevimbra |
| Beigene USA, INC. | $28.23 | 2024 | Brukinsa |
| Advanced Accelerator Applications | $27.01 | 2020 | |
| Amneal Pharmaceuticals LLC | $25.61 | 2024 | Avastin |
| Lilly USA, LLC | $22.60 | 2025 | Verzenio, Jaypirca |
| Verastem, INC. | $21.97 | 2019 | |
| Adaptive Biotechnologies Corporation | $21.93 | 2024 | Clonoseq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.52 | 2024 | |
| Springworks Therapeutics, INC. | $19.12 | 2024 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $18.55 | 2025 | Romvimza, Qinlock |
| Pharmacosmos Therapeutics INC. | $17.66 | 2025 | Monoferric |
| Azurity Pharmaceuticals, INC. | $17.48 | 2025 | Danziten |
| Rigel Pharmaceuticals, INC. | $17.44 | 2023 | Rezlidhia, Tavalisse |
| Verity Pharmaceuticals INC. | $16.87 | 2025 | Trelstar |
| Myovant Sciences INC. | $13.81 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.76 | 2020 | |
| Clovis Oncology, INC. | $5.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sprandio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.